
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb is poised to see continued success in the future due to its strong focus on immuno-oncology and upcoming clinical data readouts for key treatments such as ADEPT-2 and ADMILPARANT. However, potential risks in clinical trials and competition from other innovations could pose challenges for the company's earnings in the future. It is important to closely monitor the progress of these clinical trials and the competitive landscape in the market.
Bears say
Bristol-Myers Squibb is heavily reliant on the US market, with close to 70% of its total sales coming from the country. While the company is a leader in immuno-oncology and has a strong pipeline, there are downside risks such as potential competition in rare cardiovascular diseases, clinical failure of pipeline programs, and regulatory delays. These risks could negatively impact the company's growth and performance.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares